SI-BONE FY2025 EPS Forecast Reduced by Cantor Fitzgerald

SI-BONE, Inc. (NASDAQ:SIBN) – Stock analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of SI-BONE in a research report issued to clients and investors on Tuesday, February 25th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of ($0.64) for the year, down from their prior estimate of ($0.19). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The business had revenue of $49.00 million during the quarter, compared to analyst estimates of $48.87 million.

Other equities analysts also recently issued reports about the stock. Truist Financial reaffirmed a “buy” rating and issued a $22.00 price target (up from $18.00) on shares of SI-BONE in a research note on Tuesday. Needham & Company LLC upped their target price on SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $24.50.

SI-BONE Stock Down 1.9 %

SIBN stock opened at $17.81 on Thursday. The company has a 50 day moving average of $16.01 and a two-hundred day moving average of $14.76. The company has a market cap of $746.92 million, a price-to-earnings ratio of -19.36 and a beta of 1.17. SI-BONE has a 12-month low of $11.70 and a 12-month high of $19.16. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

Institutional Trading of SI-BONE

Several large investors have recently modified their holdings of SIBN. FMR LLC lifted its position in SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Virtus Fund Advisers LLC bought a new position in shares of SI-BONE in the fourth quarter worth about $40,000. Mainstream Capital Management LLC acquired a new position in shares of SI-BONE during the 4th quarter worth about $53,000. R Squared Ltd bought a new stake in SI-BONE during the 4th quarter valued at approximately $73,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in SI-BONE in the 4th quarter valued at approximately $97,000. 98.11% of the stock is owned by institutional investors.

Insider Activity

In other SI-BONE news, insider Anthony J. Recupero sold 3,670 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the sale, the insider now owns 222,814 shares of the company’s stock, valued at $3,097,114.60. This represents a 1.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the transaction, the chief financial officer now owns 189,319 shares in the company, valued at approximately $2,633,427.29. This trade represents a 2.73 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,311 shares of company stock worth $130,356. 3.90% of the stock is owned by corporate insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.